Tag: treatment

WESTON, Fla., July 08, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, today announced its entry into a warrant inducement agreement with a single institutional investor of the Company. Terms of the warrant inducement agreement include the immediate exercise of Series A-2 Warrants to purchase up to 957,200 shares of common stock (the “Series A-2 Warrants”) and Series A-3 Warrants to purchase up to 2,105,265 shares of common stock (the “Series A-3 Warrants,” and together with the Series A-2 Warrants, the “Existing Warrants”) at a reduced exercise price of $0.67. Gross cash proceeds were approximately $2.0 million before deducting financial advisor fees and other transaction expenses. The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes.

In this 2025 product transparency update, BloodVitals details how its pulse oximeter supports real-time blood vitals tracking through non-invasive technology designed for seniors and at-home wellness users. The release explores the shift toward pain-free health monitoring, the rising demand for accessible oxygen level tools, and the increasing role of pulse oximeters in managing vital signs outside clinical settings.

IRVINE, CA., July 08, 2025 (GLOBE NEWSWIRE) -- Clean Energy Technologies, Inc. (Nasdaq: CETY) (the “Company” or “CETY”), a clean energy technology company offering power generation, waste to energy, battery storage, and heat to power solutions to deliver affordable, scalable, and eco-friendly energy, clean fuels, and alternative electricity for a sustainable future, is pleased to announce that its technologies should remain fully eligible for federal clean energy tax incentives following the passage of the One Big Beautiful Bill Act (OBBBA), signed into law on July 4, 2025.

BOCA RATON, FL, July 08, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company”) the first public company with a treasury strategy built to accumulate and compound Solana (“SOL”), announced today the purchase of 47,272 Solana (“SOL”) at an average purchase price of $149.09 and valued at approximately $7.03 million. Following the transaction, DeFi Development Corp. now holds a total of approximately 690,420 SOL and SOL equivalents, valued at approximately $102.7 million, inclusive of staking rewards. The latest purchase marks a +64.1% increase in the Company’s SOL and SOL equivalent holdings compared to 420,690 SOL held 60 days prior.

A new category of plant-based formulations is gaining attention for their role in supporting internal balance and inflammation-linked metabolic concerns. Among these is SlimJaro, which features botanical ingredients studied for their relation to digestion, inflammation, and cortisol support

More Than Doubles H2O America’s Connections in Texas and Increases Exposure to High Growth Houston Region